Melanoma and Cardiovascular Deaths Rose in Older Americans Over Two Decades
Deaths in which melanoma and cardiovascular disease appeared together on the death certificate increased among older US adults from 1999 through 2020, drawing a sharp line through two conditions that often travel together in late life. The pattern is not a measure of cardiovascular risk among people living with melanoma, but it does reveal how often these diseases converged at the end of life in a population already burdened by both cancer and chronic vascular illness.
Between 1999 and 2020, 39,190 deaths involving both conditions were recorded among adults aged 65 years or older. More than a third, 36.8%, occurred at home. The age-adjusted mortality rate rose from 3.8 to 5.0 per 100,000, with an annual percent change of 0.95% (95% CI 0.64 to 1.31). The increase was steady enough to register as a population signal rather than a one-year fluctuation.
Men Carried a Much Higher Mortality Burden Than Women
Sex differences were striking. Men had an age-adjusted mortality rate of 7.0, compared with 2.5 in women. In practical clinical terms, that gap points to the combined influence of melanoma biology, delayed diagnosis, sun exposure history, competing vascular risk, and survivor patterns that differ by sex in older age groups. When melanoma is layered onto the vascular vulnerability of aging, men appear to have carried a much larger share of the mortality burden.
The racial gradient was equally clear. Non-Hispanic White adults had the highest age-adjusted mortality rate at 5.0, followed by Hispanics at 1.3 and non-Hispanic Black adults at 0.8. Those differences likely reflect a mix of melanoma incidence, stage at diagnosis, access to specialty care, background cardiovascular risk, and structural inequities that shape cancer outcomes across the life course. In an older population, late presentation can matter as much as treatment access, because both melanoma progression and cardiovascular instability can narrow the window for intervention.
Geography Shaped the Death Pattern as Much as Demography
Place mattered in a way that will be familiar to clinicians working outside major academic centers. Final-segment annual percent change reached 10.38% in nonmetropolitan counties from 2018 to 2020, while metropolitan counties showed a 3.44% increase from 2016 to 2020; those segments are not directly comparable. Still, the direction is hard to ignore. Older adults in less populated counties may face longer travel times, thinner specialty coverage, later cancer detection, and fewer options for coordinated oncology and cardiovascular care.
Regional variation also persisted. The West had the highest regional age-adjusted mortality rate at 5.1. Across states, rates ranged from 1.4 in the District of Columbia to 6.1 in California, Oklahoma, and Nebraska, with overlapping confidence intervals. Overlapping intervals prevent overinterpretation of any single state rank, but they do not erase the broader geography: mortality involving melanoma and cardiovascular disease was unevenly distributed across the country.
End-of-Life Location Points to Complex Care Needs
The fact that 36.8% of these deaths occurred at home suggests that many older adults were living with advanced illness in the community, not in a hospital bed. Home death can reflect patient preference, hospice involvement, or a clinical course in which escalation was no longer appropriate. It can also signal that cardiovascular events, cancer progression, or both were unfolding in a setting where symptom control and care coordination became more important than curative treatment.
From a bedside perspective, melanoma in an older adult rarely exists in isolation. Aging brings hypertension, atherosclerosis, arrhythmia, heart failure, and polypharmacy into the same room as skin cancer. Cardiovascular disease can limit surgical candidacy, complicate systemic therapy, and worsen resilience during acute illness. Conversely, cancer-related inflammation, frailty, and treatment toxicity can destabilize vascular disease. The mortality pattern reflects that interaction, even though the analysis does not assign causality to any one pathway.
Death Certificates Capture a Signal, Not a Causal Chain
This was a death-certificate study using the CDC WONDER Multiple Cause of Death database, and its strength lies in scale rather than mechanistic precision. Death certificates can identify when both melanoma and cardiovascular disease were listed as underlying or contributing causes, but they cannot determine which disease drove the terminal event, whether therapy contributed, or how often a patient was living with both conditions for years versus days. The analysis also does not estimate cardiovascular mortality risk among patients with melanoma.
Even with that constraint, the epidemiologic signal is clinically useful. Older adults represent the segment of the population most likely to accumulate both oncologic and vascular disease, and mortality trends in that group can expose where prevention, survivorship care, and palliative planning are failing to keep pace. Rising rates in this dataset argue for closer attention to cardiovascular optimization in older adults with melanoma, especially in men, non-Hispanic White populations, and residents of nonmetropolitan areas.
Targeted Prevention Will Have to Follow the Geography of Risk
The most actionable implication is not a new drug or a new procedure. It is a care model that recognizes melanoma as part of a broader geriatric risk profile. Earlier skin cancer detection, tighter cardiovascular management, and better coordination between dermatology, oncology, primary care, and cardiology may matter most where the mortality curve is climbing fastest.
The study received no external funding and involved publicly available data, so the findings stand as a population-level warning rather than a clinical trial result. The core question now is how much of this burden is modifiable through earlier diagnosis, improved access to specialist care, and more deliberate management of cardiovascular comorbidity in older adults living with melanoma.